In 2014, after the first CTLA-4 monoclonal antibody was approved by the US FDA (34), the PD-1 monoclonal antibody was again approved by the FDA for the treatment of metastatic melanoma (35). The gene discussed is CTLA4; the disease is metastatic melanoma.